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Abstract 
Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase 
(PARP) with demonstrated efficacy in patients with BRCA-mutated ovarian cancer, is 
mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). We 
assessed the potential of a CYP3A4 inhibitor (itraconazole) and inducer (rifampin) to 
alter the pharmacokinetic (PK) profile of olaparib following single oral tablet doses. 
Methods: Two Phase I, open-label, non-randomized trials were conducted in patients 
with advanced solid tumors. In Study 7 (NCT01900028) patients received olaparib alone 
and co-administered with itraconazole, and in Study 8 (NCT01929603) olaparib alone 
and co-administered with rifampin. No interaction between itraconazole and olaparib 
was to be concluded if 2-sided 90% confidence intervals (CIs) for the treatment ratios of 
area under the curve (AUC; and/or AUC0–t) and maximum plasma concentration (Cmax) 
fell within the bioequivalence range of 0.80–1.25. An interaction between rifampin and 
olaparib was to be concluded if the lower limit of the 90% CI for the treatment ratios was 
<0.5 (ie, >50% decrease in olaparib AUC or Cmax in the presence of rifampin compared 
with olaparib alone). 
Findings: In Study 7 (N=59 patients), 56 and 53 patients were evaluable for PK analysis 
following treatment with olaparib alone and olaparib plus itraconazole, respectively. In 
Study 8 (N=22), all patients were evaluable for PK. Co-administration of olaparib with 
itraconazole resulted in a statistically significant increase in the relative bioavailability of 
olaparib: Cmax treatment ratio 1.42 (90% CI: 1.33, 1.52) and mean AUC treatment ratio 
2.70 (90% CI: 2.44, 2.97). The mean apparent plasma clearance (CL/F) and apparent 
volume of distribution (Vz/F) were reduced (8.16 vs 3.05 L/hour, and 192 vs 75.1 L, 
respectively) although mean t½ was unchanged (15.0 vs 15.6 hours). Co-administration 
of olaparib with rifampin resulted in a statistically significant decrease in the relative 
bioavailability of olaparib: Cmax treatment ratio 0.29 (90% CI: 0.24, 0.33) and mean AUC 
treatment ratio 0.13 (90% CI: 0.11, 0.16). CL/F and Vz/F were increased when olaparib 
and rifampin were co-administered (6.36 vs 48.3 L/hour and 112 vs 1076 L, 
respectively); however, mean t½ was unchanged (13.0 vs 15.8 hours). Safety data for 
olaparib following tablet dosing were consistent with the known safety profile. 
Implications: Exposure to olaparib was significantly increased when co-administered 
with the CYP3A4 inhibitor, itraconazole, and significantly decreased when 
co-administered with the CYP3A4 inducer, rifampin, compared with olaparib alone. 
CYP3A4 enzyme inhibitors and inducers should be avoided during olaparib treatment.  
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Introduction 
Olaparib (Lynparza™) is a potent, oral, poly(ADP-ribose) polymerase (PARP) inhibitor 
that blocks base-excision repair of single-strand DNA breaks by trapping PARP at sites 
of DNA damage.1 PARP inhibitors also impair, via other mechanisms, high fidelity repair 
of double-strand DNA breaks in tumor cells with deficiencies in homologous 
recombination repair (HRR), such as BRCA1/2 mutations (BRCA1/2m).2,3 Impaired DNA 
repair in tumor cells with HRR deficiencies leads to irreparable double-strand breaks 
being formed that result in tumor cell death by synthetic lethality.4 PARP inhibitors can 
also induce lethality in tumor cells that have deficiencies in DNA damage repair 
mechanisms other than HRR deficiencies.  
In 2014 olaparib (capsule formulation) became the first PARP inhibitor approved for 
treatment when the United States Food and Drug Administration (FDA) granted 
accelerated approval of olaparib for the monotherapy treatment of patients with relapsed 
germline BRCAm (gBRCAm) ovarian cancer who have received three or more lines of 
chemotherapy.5 The European Medicines Agency (EMA) also granted approval of 
olaparib as monotherapy maintenance treatment of adult patients with platinum-
sensitive, relapsed BRCAm (germline and/or somatic) ovarian cancer who are in 
response to platinum-based chemotherapy based on Study 19 data.6 In patients with 
platinum-sensitive, recurrent serous ovarian cancer, maintenance monotherapy with a 
capsule formulation of olaparib 400 mg bid significantly prolonged progression-free 
survival (PFS) versus placebo.7 Further analysis of this patient population has shown 
that patients with a BRCAm receive greater treatment benefit.8 In a study of patients with 
a germline BRCA1/2m and solid tumors refractory to standard therapy, treatment with a 
capsule formulation of olaparib 400 mg bid prolonged tumor responses across a 
spectrum of malignancies, including ovarian, breast, pancreatic, and prostate cancers.9 
To receive the recommended 400 mg bid dose of olaparib, patients are required to take 
16 x 50 mg large capsules per day and consequently patient compliance may be 
compromised. A tablet formulation has therefore been developed to deliver a therapeutic 
dose in fewer and smaller units. A recommended tablet dose of 300 mg bid has been 
determined in a Phase I trial (Study 24, NCT00777582) for administration in Phase III 
studies. [Study 24 primary manuscript to be cited when appropriate]10  
In vitro data have shown the metabolism of olaparib is mediated by cytochrome P450 
(CYP) enzymes (predominantly CYP3A4/5), therefore, co-administration with potent 
inhibitors or inducers of CYP3A4 would be expected to alter the pharmacokinetics (PK) 
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of olaparib [McCormick & Swaisland, in preparation]. Since patients receiving olaparib 
are likely to be taking multiple medications, significant PK drug‒drug interactions could 
lead to alterations in plasma concentrations of olaparib, potentially resulting in a 
reduction in efficacy or an increase in drug-related toxicity. 
The results of two clinical studies, which investigated the potential for PK interactions 
between either olaparib (tablet formulation) and itraconazole, an antifungal agent and 
potent CYP3A4 inhibitor (Study 7), or olaparib and rifampin, a bactericidal antibiotic and 
potent CYP3A4 inducer (Study 8) are reported.  
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Patients and methods 
Study design 
Both studies were Phase I, open-label, non-randomized, multicenter trials in patients 
with advanced solid tumors (Study 7: NCT01900028 [D0816C00007] and Study 8: 
NCT01929603 [D0816C00008]). Study 7 consisted of three parts (A‒C) and Study 8 two 
parts (A and B) (Figure 1).  
 
Figure 1. Study designs 
 
 
 
In both studies, Part A assessed the effect of either the CYP3A4 inhibitor (Study 7) or 
CYP3A4 inducer (Study 8) on the PK profile of olaparib following single dosing of the 
tablet formulation, and only data from this part of each study are reported in this 
manuscript. Data from Study 7 Part B (assessment of the effect of olaparib on the QT 
interval following multiple oral dosing of olaparib tablets) and Part C (long-term safety), 
and from Study 8 Part B (long-term safety), will be reported separately.  
In Study 7, Part A consisted of a non-randomized, open-label, sequential, two-treatment 
design. Patients received a single oral dose of olaparib 100 mg (1 x 100 mg tablet) on 
day 1 after a 10-hour fast, and a single oral dose of olaparib 100 mg (1 x 100 mg tablet) 
administered concurrently with itraconazole 200 mg (2 x 100 mg tablets) on day 9 after 
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an overnight fast. Itraconazole 200 mg was administered once daily on days 5–11 with a 
full meal (except for the dose on day 9).  
In Study 8, Part A also consisted of a non-randomized, open-label, sequential, 
two-treatment design. Patients received a single oral dose of olaparib 300 mg (2 x 150 
mg tablets) on day 1, and a single oral dose of olaparib 300 mg (2 x 150 mg tablets) 
administered concurrently with rifampin 600 mg (2 x 300 mg tablets) on day 14. The 
treatments on days 1 and 14 were administered following an overnight fast, and patients 
remained fasting for 2 hours post-dose. Rifampin 600 mg (2 x 300 mg tablets) was 
administered once daily following an overnight fast on days 5–17.  
 
Study population 
In both studies, eligible patients were aged ≥18 years and had a confirmed 
(histologically, or where appropriate, cytologically) malignant solid tumor refractory or 
resistant to standard therapy and for which no suitable standard therapy exists. Patients 
also needed to have a life expectancy of ≥16 weeks, an Eastern Cooperative Oncology 
Group (ECOG) performance status ≤2, and adequate organ and bone marrow function 
measured within 28 days prior to administration of olaparib. Patients were excluded if 
they had recently received or were receiving medications known to be inhibitors or 
inducers of CYP3A4. Additionally, any intake of grapefruit or Seville oranges, or 
products containing these components was not permitted within 7 days prior to olaparib 
dosing. Patients were required to be on a stable concomitant medication regimen (with 
the exception of electrolyte supplements), defined as no changes in medication or in 
dose within 2 weeks prior to olaparib dosing, except for bisphosphonates, denosumab 
and corticosteroids, which needed to be stable for at least 4 weeks prior to the start of 
olaparib dosing.  
The institutional review boards or independent ethics committees of all investigational 
sites approved both protocols, and the studies were performed in accordance with the 
Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on 
Bioethics.11 All patients provided written informed consent. 
 
Study objectives 
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Primary and secondary objectives included investigation of the effect of itraconazole 
(Study 7) or rifampin (Study 8) on the PK profile of olaparib following oral dosing of the 
tablet formulation in patients with advanced solid tumors; to demonstrate exposure to 
itraconazole and its metabolite hydroxyitraconazole (Study 7); to demonstrate exposure 
to rifampin and induction of CYP by rifampin (assessed by determining plasma 
concentrations of 4β-hydroxycholesterol, a biomarker for CYP3A4 activity)12,13 (Study 8); 
and to further investigate the safety and tolerability of olaparib tablets in patients with 
advanced solid tumors (both studies). 
 
Pharmacokinetic assessment 
Blood samples for determination of olaparib concentrations were taken on days 1 and 9 
for Study 7, and on days 1 and 14 for Study 8 as follows: pre-dose, and at 0.25, 0.5, 1, 
1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose. 
Blood samples for determination of itraconazole and hydroxyitraconazole concentrations 
were taken on day 9, pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-
dose. Blood samples for determination of rifampin concentrations were taken on days 5, 
9, 14 and 17 at 2 hours post-dose and blood samples for determination of 4β-
hydroxycholesterol were taken on days 5, 9, 14 and 17 prior to administration of 
rifampin.  
The determination of drug concentrations (olaparib, itraconazole/metabolite, rifampicin) 
and the PK analyses of these concentrations were conducted by Covance Laboratories 
in Harrogate, UK and Alnwick, UK, respectively.14 Analyses of 4β-hydroxycholesterol 
were conducted by PRA International, Assen, The Netherlands.15 PK parameters were 
determined using standard, non-compartmental analysis: maximum plasma 
concentration (Cmax), area under the plasma concentration time curve (AUC) from zero 
(pre-dose) to infinity, AUC from zero to time of last quantifiable sample (AUC0-t), time to 
maximum plasma concentration (tmax), terminal half-life (t½), apparent clearance (CL/F), 
and apparent volume of distribution (Vz/F). PK parameters determined for itraconazole 
included Cmax, AUC over the dosing interval AUCtau, tmax, and CL/F, and for 
hydroxyitraconazole included Cmax, AUCtau, and tmax. PK computations were performed 
using Phoenix™ for WinNonlin. Plasma concentrations of rifampin and 4β-
hydroxycholesterol were summarized. 
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Patients were monitored for adverse events (AEs) throughout both studies. AEs were 
graded according to the National Cancer Institute Common Terminology Criteria (NCI-
CTC) version 4. All serious AEs (SAEs) and AEs related to treatment were followed up 
to resolution. For both studies, AEs were summarized separately for the olaparib alone 
and olaparib plus itraconazole/rifampin dosing periods. For the olaparib plus 
itraconazole/rifampin dosing period, only new AEs occurring from the first dose of 
olaparib plus itraconazole/rifampin were included; ongoing AEs from the olaparib-alone 
dosing period were not included. Clinical laboratory, vital signs and physical examination 
parameters were also evaluated. 
 
Statistical analyses 
The PK analysis set included all patients who received an olaparib dose and provided 
evaluable PK profiles in at least one treatment period, ie, olaparib or olaparib plus 
itraconazole/rifampin. The safety analysis set (patients evaluable for safety) included all 
patients who received at least one dose of olaparib and for whom any post-dose data 
were available. Safety data are presented descriptively. 
In both studies, the primary PK outcome variables of olaparib AUC, or AUC0-t if AUC was 
not adequately estimable, and Cmax were statistically analyzed to investigate the effect of 
itraconazole or rifampin on the PK of olaparib. Following log-transformation, Cmax, AUC, 
and AUC0-t were analyzed separately by mixed-effect analysis of variance (ANOVA), 
fitting terms for treatment as a fixed effect and patient as a random effect. Point 
estimates and adjusted 90% confidence intervals (CIs) for the difference between 
treatments (olaparib co-administered with itraconazole or rifampin compared with 
olaparib alone) for Cmax, AUC, and AUC0-t were constructed. The point estimate and 
adjusted 90% CIs were then exponentially back transformed to provide point and CI 
estimates for the ratio of interest.  
An analysis of tmax using the Wilcoxon signed rank test, and the Lehman median 
estimator of difference, (olaparib co-administered with itraconazole or rifampin compared 
with olaparib alone) and 90% CIs were also presented. All summaries and statistical 
analyses were performed using SAS® version 8.1 or higher. 
Determination of sample size 
In Study 7, recruitment of approximately 48 patients was planned to ensure 42 evaluable 
patients completed the study. This sample size of 42 patients was required to give 90% 
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power to rule out a 20% change in log-transformed AUC (and/or AUC0-t) and Cmax of 
olaparib, ie, if the true effect of itraconazole on olaparib exposure was minimal, the 90% 
CI treatment ratio would be entirely within the bioequivalence range of 0.80 to 1.25. 
Accordingly, no interaction of itraconazole on the PK of olaparib was to be concluded if 
the 2-sided 90% CIs for the treatment ratios of AUC (and/or AUC0-t) and Cmax fell entirely 
within the bioequivalence range of 0.80 to 1.25. 
 
In Study 8, recruitment of approximately 18 patients was planned to ensure 16 evaluable 
patients completed the study; 16 evaluable patients were required to give 90% power to 
rule out a halving of log-transformed AUC (and/or AUC0-t) and Cmax of olaparib in the 
presence of rifampin, indicated by a 90% CI for the treatment ratio entirely above 0.5. 
Accordingly, no interaction between olaparib and rifampin was to be considered to have 
occurred if the lower limit of the 90% CI for the treatment ratios was greater than 0.5  
(ie, less than a 50% decrease in olaparib AUC or Cmax in the presence of rifampin, 
compared with olaparib alone). 
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Results 
Patients 
Table 1 shows the demographics and baseline characteristics of patients in Study 7 and 
8. Between 2013 and 2014, 59 patients (17 male and 42 female) were assigned to Study 
7, received at least one dose of olaparib, and completed Part A; patients were recruited 
from 11 centers in four countries. Between 2013 and 2014, 22 patients (4 male and 18 
female) were assigned to treatment into Part A and received at least one dose of 
olaparib in Study 8; patients were recruited from five centers in two countries. 
In both studies the majority of patients had an ECOG performance status ≤1 and the 
most common primary tumor type was ovarian (Table 1). 
 
Table 1. Summary of patient demographics and baseline clinical characteristics 
(safety analysis set) 
 Study 7 
N=59 
Study 8 
N=22 
Median age (range), years 61.0 (34‒82) 59.0 (31‒79) 
Gender, n (%) 
Male 
Female 
 
17 (28.8) 
42 (71.2) 
 
4 (18.2) 
18 (81.8) 
Race, n (%) 
White 
Asian 
Black/African American 
Other 
 
55 (93.2) 
2 (3.4) 
1 (1.7) 
1 (1.7) 
 
22 (100) 
0 
0 
0 
Weight, mean,  kg (SD) 74.6 (19.4) 74.2 (14.0) 
BMI, mean, kg/m2 (SD) 26.6 (5.7) 26.2 (4.4) 
ECOG performance status, n (%)* 
0 
1 
2 
 
25 (42.4) 
32 (54.2) 
2 (3.4) 
 
7 (31.8) 
11 (50.0) 
3 (13.6) 
Tumor type, n (%) 
Ovarian (including fallopian tube) 
Colorectal 
Pancreatic 
Breast 
 
 
21 (35.6) 
10 (16.9) 
7 (11.9) 
3 (5.1) 
 
 
7 (31.8) 
3 (13.6) 
0 
5 (22.7) 
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Lung  
Cervical 
Peritoneal 
Head and neck 
Biliary tract 
Uterine 
Bladder (including urethra) 
Other†‡ 
 
3 (5.1) 
3 (5.1) 
2 (3.4) 
2 (3.4) 
2 (3.4) 
2 (3.4) 
1 (1.7) 
2 (3.4) 
 
0 
0 
0 
0 
0 
0 
3 (13.6) 
4 (18.2) 
Disease classification, n (%) 
Metastatic 
Locally advanced 
 
 
53 (89.8) 
6 (10.2) 
 
 
20 (90.9) 
2 (9.1) 
 
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation. 
*Data were missing for one patient in Study 8 who had metastatic well differentiated (G1) colon cancer; †Data were missing for 
one patient in Study 7; ‡Other primary tumor locations were central nervous system, and bilio-pancreas in Study 7. Adrenal and 
prostate in one patient each, and cancer of unknown primary in two patients in Study 8; ECOG performance status and overall 
disease classification were based on assessments at baseline. Primary tumor types are based on assessments at diagnosis.  
 
Pharmacokinetics 
Study 7 (CYP3A4 inhibition) 
Out of the 59 patients assigned to treatment, 56 and 53 patient profiles were evaluable 
for the olaparib-alone dosing period and the olaparib and itraconazole dosing period, 
respectively. Three patients were excluded from both dosing periods due to a disallowed 
surgical procedure (having previously had a gastric band fitted), baseline creatinine >50 
mL/min, and incorrect sample handling. Three additional patients were excluded from 
the olaparib and itraconazole dosing period due to a full itraconazole dose not being 
administered, incorrect formulation of itraconazole used (liquid rather than tablet), and 
PK samples not provided. Although the protocol planned to enrol 48 evaluable patients, 
11 additional patients were recruited and randomized to treatment to ensure sufficient 
patient numbers were available for a later part of the study (effect of olaparib on the QT 
interval – to be reported separately).  
Following a single oral administration of olaparib alone (100 mg tablet) in fasted 
conditions, the drug appeared rapidly in plasma, with peak concentrations typically 
observed 1 hour after dosing. Following dosing in combination with itraconazole, median 
tmax was slightly later (1.5 hours). Beyond the peak, plasma concentrations in both 
treatment arms generally declined in a biphasic manner, remaining above the limit of 
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quantification of the assay for up to 72 hours after dosing in the majority of patients 
where sampling continued to that point (Figure 2).  
 
Figure 2. Geometric mean plasma concentration of olaparib over time following  
a single dose of olaparib alone, or in combination with (a) itraconazole or  
(b) rifampin 
  
 
  
Consistent with the increase in AUC, mean apparent plasma clearance (CL/F) and 
apparent volume of distribution (Vz/F) were reduced when olaparib was dosed in 
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combination with itraconazole, 8.16 L/hour vs 3.05 L/hour, and 192 L vs 75.1 L, 
respectively. However, the mean t½ of olaparib was unchanged, 15.0 hours vs 15.6 
hours, respectively for olaparib alone versus olaparib co-administered with itraconazole 
(Table 2). 
 
Table 2. Pharmacokinetic parameters of single-dose olaparib alone or in 
combination with itraconazole or rifampin 
 
Study 7 (itraconazole)  
N=57 
Study 8 (rifampin) 
N=22 
PK parameter 
Olaparib alone 
(100 mg) 
 
 
Olaparib  
(100 mg) plus 
itraconazole 
(200 mg) 
Olaparib alone 
(300 mg) 
 
Olaparib  
(300 mg) plus 
rifampin  
(600 mg) 
n 
Cmax, µg/mL (GCV, %) 
56 
2.99 (48.2) 
53 
4.24 (37.7) 
22 
8.05 (24.3) 
18  
2.24 (53.4) 
n 
tmax, h (min,max) 
56 
1.03 (0.48‒
8.25) 
53 
1.50 (0.50‒
12.00) 
22 
1.49 
(0.57‒3.05) 
18 
0.78  
(0.27‒5.95) 
n 
AUC, µg/mL (GCV, %) 
53 
14.78 (75.4) 
49 
40.09 (72.1) 
21 
55.20 (67.4) 
17  
6.79 (46.4) 
n 
AUC(0‒t), µg/mL 
(GCV, %) 
52 
15.21 (76.0) 
52 
39.52 (68.8) 
22 
54.60 (63.8) 
18  
6.19 (60.2) 
n 
t½, h (SD) 
53 
15.01 (8.23) 
49 
15.55 (6.44) 
21 
13.02 (4.16) 
17  
15.80 (9.55) 
n 
CL/F, L/h (SD) 
53 
8.16 (4.61) 
49 
3.05 (2.10) 
21 
6.36 (3.47) 
17 
48.3 (21.04) 
n 
Vz/F, L (SD) 
53 
191.8 (172.4) 
49 
75.14 (81.27) 
21 
112.1 (59.84) 
17 
1076 (868.8) 
AUC, area under plasma concentration–time curve from zero to infinity; AUC(0–t), area under plasma concentration–time curve 
from zero to the last measurable time point; CL/F, apparent clearance following oral administration; Cmax, maximum plasma 
concentration; tmax, time to maximal plasma concentration; t½, terminal half-life; Vz/F, apparent volume of distribution.  
n is the number of patients with non-missing data. N is the PK analysis set (all patients who received at least one dose of study 
treatment and provided evaluable PK profiles in at least one treatment period). n is the number of patients with non-missing 
data; Data are expressed as geometric mean (CV%) for Cmax, AUC and AUC(0–t); arithmetic mean (standard deviation) for CL/F, 
Vz/F and t½; and median (range) for tmax. 
 
Co-administration of olaparib with itraconazole resulted in a significant increase in the 
relative bioavailability of olaparib compared with olaparib administered alone: Cmax 
treatment ratio 1.42 (90% CI: 1.33, 1.52) and mean AUC treatment ratio 2.70 (90% CI: 
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2.44, 2.97) (Table 3). For individual patients, the highest observed ratio for AUC was a 
7-fold increase. 
 
Table 3. Relative bioavailability of single-dose olaparib alone or in combination 
with itraconazole or rifampin  
PK parameter  
 
GLS mean 
ratio (90% CI) 
Study 7  
(itraconazole) 
Study 8  
(rifampin) 
Olaparib (100 mg) 
plus itraconazole (200 mg) 
vs olaparib (100 mg) 
Olaparib (300 mg) 
plus  rifampin (600 mg) 
vs olaparib (300 mg) 
Cmax, µg/mL 1.42 (1.33, 1.52) 0.29 (0.24, 0.33) 
AUC, µg h/mL 2.70 (2.44, 2.97) 0.13 (0.11, 0.16) 
AUC0‒t, µg h/mL 2.66 (2.41, 2.93) 0.12 (0.10, 0.15) 
AUC, area under plasma concentration–time curve from zero to infinity; AUC0–t, area under plasma concentration–
time curve from zero to the last measurable time point; Cmax, maximum plasma concentration; GLS, geometric 
least squares. 
 
Cmax and AUC for itraconazole and hydroxyitraconazole determined after 5 days 
administration of itraconazole (200 mg once daily) are shown in Table 4.  
 
Table 4. Pharmacokinetic parameters for itraconazole and hydroxyitraconazole 
obtained on the fifth day of itraconazole dosing (Study 7) 
PK parameter 
Itraconazole 
(n=53) 
Hydroxyitraconazole 
(n=53) 
Cmax, ng/mL (GCV, %) 245.5 (107.2) 
 
313.3 (101.5) 
 
tmax, h (min,max) 3.00 (1.00‒12.00) 
 
4.00 (0.00‒8.03) 
 
AUCtau, µg.h/mL (GCV, %) 2702 (108.1) 5341 (127.6) 
 
CL/F, L/h (GCV, %) 74.02 (108.1) ND 
AUCtau, area under plasma concentration–time curve for a dosing interval; CL/F, apparent clearance following  
oral administration; Cmax, maximum plasma concentration; GCV, geometric coefficient of variation; ND, not determined; tmax, 
time to maximal plasma concentration. n is the number of patients with non-missing data. Data are expressed as geometric 
mean (geometric CV%) for Cmax, AUCtau; arithmetic mean (standard deviation) for CL/F; and median (range) for tmax. 
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All patients in the olaparib plus itraconazole treatment arm were shown to have been 
exposed to itraconazole and its metabolite. Steady state exposures (Cmax and AUC) for 
itraconazole and hydroxyitraconazole, determined after 5 days’ administration of 
itraconazole (200 mg once daily), were of a similar order of magnitude to the exposures 
reported in other clinical PK studies utilizing a similar dosing regimen where significant 
interactions have been demonstrated (the mean itraconazole previously reported was 
324 ng/mL).16 In six patients, however, the plasma concentrations achieved for both 
itraconazole and hydroxyitraconazole appeared low, with the observed itraconazole Cmax 
being less than 100 ng/mL (range 14.6 to 71.6 ng/mL). There was no clear evidence that 
these patients were those where the smallest effect was seen on olaparib suggesting 
that sufficient itraconazole exposure to inhibit CYP3A4 had still been achieved in these 
patients.  
 
Study 8 (CYP3A4 induction) 
All 22 patients had evaluable PK profiles with no important protocol deviations that 
impacted PK. The olaparib plasma concentration versus time profiles in the absence and 
presence of rifampin are shown in Figure 2b.  
The rate of absorption of olaparib (300 mg) was increased when administered in the 
presence of rifampin, with a median tmax of 0.78 hours (range: 0.27–5.95 hours) 
compared with olaparib administered alone (1.49 hours, range: 0.57–3.05 hours) (Table 
2). Co-administration of olaparib with rifampin resulted in a statistically significant 
decrease of approximately 71% in the relative bioavailability of olaparib; Cmax treatment 
ratio 0.29 (90% CI: 0.24, 0.33). Mean AUC was also reduced by 87% in the presence of 
rifampin compared with olaparib administered alone; treatment ratio 0.13 (90% CI: 0.11, 
0.16) (Table 3). 
Consistent with the decrease in AUC of olaparib, mean apparent CL/F increased by 7.6-
fold (6.36 vs 48.3 L/hour) and mean apparent Vz/F by 9.6-fold (112 vs 1076 L) following 
dosing in the presence of rifampin (Table 2). However, there was no marked change in 
t½ compared with olaparib administered alone (13 hours for olaparib alone vs 15.8 hours 
in combination with rifampin).  
Overall, mean plasma concentrations of rifampin were generally consistent on all study 
days, suggesting that steady-state exposures had been maintained throughout the study 
period (Figure 3a).  
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Following administration of rifampin (600 mg), mean plasma 4β-hydroxycholesterol 
levels increased by approximately 5-fold (from 55.2 nmol/L on day 5 to 316 nmol/L by 
day 17; ratio: 5.31, 90% CI: 4.68, 6.02), indicating that CYP3A4 enzyme induction had 
occurred (Figure 3b). 
 
Figure 3. Geometric mean plasma concentration of (a) rifampin over time: log 
scale and (b) 4β-hydroxycholesterol over time: log scale 
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Safety and tolerability 
Study 7 (CYP3A4 inhibition) 
In Study 7, a total of 42 (71.2%) patients reported 135 AEs. In the olaparib-alone dosing 
period nine (15.3%) patients reported nine AEs considered by the investigator as 
causally related to olaparib (nausea, n=3; diarrhea, n=2; flushing, n=1; headache, n=1; 
rash, n=1; rash erythematous, n=1). In the olaparib plus itraconazole dosing period 
seven (11.9%) patients reported 11 AEs that were considered causally related to 
olaparib (constipation, n=2; diarrhea, n=2; nausea, n=2; abdominal pain, n=1; ascites, 
n=1; cough, n=1; headache, n=1; tinnitus, n=1). The majority of AEs were 
gastrointestinal in origin, and of common terminology criteria for adverse events 
(CTCAE) grade 2 or lower. The AEs reported by the greatest number of patients are 
shown in Table 5. 
 
Table 5. Adverse events experienced by >5% of patients overall in Study 7 or 
Study 8* 
Adverse event 
Study 7 (itraconazole) Study 8 (rifampin) 
Olaparib  
(100 mg) 
(n=59) 
Olaparib (100 mg) 
plus itraconazole 
(200 mg) 
 (n=59) 
Olaparib  
(300 mg) 
(n=22) 
Olaparib (300 mg) 
plus rifampin 
(600 mg)  
(n=22) 
Patients with any AE,  
n patients (%) 25 (42.4) 33 (55.9) 8 (36.4) 18 (81.8) 
Diarrhea 4 (6.8) 4 (6.8) 1 (4.5) 3 (13.6) 
Nausea 4 (6.8) 4 (6.8) 0 7 (31.8) 
Constipation 2 (3.4) 6 (10.2) 1 (4.5) 2 (9.1) 
Vomiting 2 (3.4) 4 (6.8) 0 6 (27.3) 
Fatigue 2 (3.4) 5 (8.5) 0 2 (9.1) 
Abdominal pain 1 (1.7) 2 (3.4) 1 (4.5) 3 (13.6) 
Cough  1 (1.7) 3 (5.1) 0 0 
Dyspepsia 1 (1.7) 2 (3.4) 0 1 (4.5) 
Headache 1 (1.7) 5 (8.5) 1 (4.5) 3 (13.6) 
Dyspnea 1 (1.7) 2 (3.4) 0 2 (9.1) 
Hypokalemia 0 3 (5.1) 0 1 (4.5) 
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Back pain 0 3 (5.1) 0 0 
Pain in extremity 0 2 (3.4) 0 2 (9.1) 
Insomnia 0 1 (1.7) 0 2 (9.1) 
Feces discolored 0 0 0 2 (9.1) 
Malaise 0 0 0 2 (9.1) 
Decreased appetite 0 0 1 (4.5) 3 (13.6) 
     
Chromaturia 0 0 0 5 (22.7) 
*AEs presented for olaparib alone and olaparib in combination should not be compared, as the combination data was evaluated 
over a longer observation period and consists primarily of administration of the putative interacting drug alone. 
 
In total, two (3.4%) and five (8.5%) patients reported a CTCAE grade 3 AE in the 
olaparib-alone dosing period (diarrhea, nausea) and in the olaparib plus itraconazole 
dosing period (anemia, fatigue, international normalised ratio increased nausea, urinary 
tract obstruction, vomiting), respectively. Two patients experienced SAEs of nausea 
(grade 2, grade 3), both in the olaparib plus itraconazole dosing period, which were 
considered by the investigator to be causally related to olaparib. No AEs considered 
causally related to olaparib treatment resulted in discontinuation of olaparib. Overall, 
there were no clinically relevant differences in clinical chemistry parameters between the 
safety profiles of olaparib when administered alone or in combination with itraconazole.  
One death was reported during the olaparib plus itraconazole dosing period. The 
reported primary cause of death was disease progression and was not reported as an 
AE.  
Study 8 (CYP3A4 induction) 
In total 19 (86.4%) patients experienced 90 AEs. Two patients (9.1%) reported three 
AEs considered causally related to olaparib (abdominal pain upper, diarrhea, headache). 
In the olaparib plus rifampin dosing period five patients (22.7%) reported 14 AEs 
considered causally related to olaparib (nausea, n=3; vomiting n=3; constipation, 
decreased appetite, diarrhea, gastrointestinal hypermotility, hemoglobin urine present, 
malaise, stomatitis, and urinary retention, all n=1). The most frequently reported AEs are 
shown in Table 5. Chromaturia, observed in five (22.7%) patients, is a known AE 
associated with rifampin treatment.17  
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Two (9.1%) patients reported two CTCAE grade 3 AEs in the olaparib-alone dosing 
period (decreased appetite, lymphoedema) and five (22.7%) patients reported eight 
CTCAE grade 3 AEs in the olaparib plus rifampin dosing period (abdominal pain, 
ascites, convulsion, fatigue, headache, malaise, neutropenia, thrombocytopenia). None 
of the SAEs reported were considered related to olaparib treatment and no AEs resulted 
in discontinuation of olaparib. 
There was one death reported during the olaparib plus rifampin dosing period. The 
reported primary cause of death was disease progression and was not reported as an 
AE.  
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Discussion 
Two Phase I, non-randomized, open-label studies were conducted to investigate the 
effect of itraconazole, a potent CYP3A4 inhibitor, or rifampin, a potent CYP3A4 inducer 
on the PK profile of olaparib following a single dose of the tablet formulation. Given that 
in vitro studies have shown that the metabolism of olaparib is mediated by CYP 
enzymes, [McCormick & Swaisland, in preparation] predominantly CYP3A4/5, the 
current Phase I studies were deemed important, as any PK interactions of olaparib with 
agents that inhibit or induce CYP3A4 could have clinical implications.  
In Study 7, CYP3A4 was inhibited by administration of itraconazole 200 mg/day for  
4 days, before dosing with a single 100 mg olaparib dose. This itraconazole regimen 
resulted in steady-state exposures of itraconazole and its metabolite, 
hydroxyitraconazole, consistent with other clinical PK studies.16 Co-administration of 
olaparib with itraconazole significantly increased olaparib mean plasma AUC by 2.7-fold, 
whilst mean Cmax increased 1.4-fold, indicating that an interaction had occurred. Since 
the treatment ratios and 90% CIs for both Cmax and AUC were outside the predefined 
bioequivalence range (0.80–1.25), these findings show that itraconazole has a 
statistically significant and potentially clinically relevant effect on olaparib. There was no 
difference in t½ of olaparib when dosed in combination with itraconazole, but both CL/F 
and Vz/F were decreased, reflecting the increased exposure to olaparib. The unchanged 
elimination t½ of olaparib despite the decreased clearance and volume of distribution 
suggests that itraconazole may predominantly affect olaparib exposure by altering its 
bioavailability, possibly through inhibition of transporter-mediated processes in the gut, 
resulting in a change in the extent of olaparib absorption.  
Preclinical data have shown that olaparib is a substrate for P-glycoprotein [McCormick & 
Swaisland, in preparation] and itraconazole is an inhibitor of this transporter system as 
well as of CYP3A4 mediated metabolism.18 Given, these findings, it is recommended 
that potent CYP3A4 enzyme inhibitors (eg, itraconazole, telithromycin, clarithromycin, 
ketoconazole, voriconazole, nefazodone, posaconazole, ritinovir, lopinavir, indinavir, 
saquinavir, nelfinavir, boceprevir, telaprevir) and moderate CYP3A inhibitors (eg, 
amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, 
erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) should be avoided during 
olaparib treatment. 
In Study 8, CYP3A4 was induced by administration of rifampin 600 mg/day for 9 days 
before dosing with a single 300 mg olaparib dose (2 x 150 mg tablets). Exposure to 
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rifampin 600 mg was of a similar magnitude to that reported in other controlled clinical 
PK studies using a similar dosing regimen where significant drug–drug interactions have 
been demonstrated.19–21 CYP3A4 enzyme induction by rifampin was shown in all 
patients by a consistent increase in the endogenous biomarker 4β-hydroxycholesterol. 
Co-administration of olaparib with rifampin significantly reduced olaparib mean plasma 
AUC by approximately 87%. There was also a significant decrease of 71% in the Cmax of 
olaparib. The treatment ratio and 90% CI for AUC and Cmax were <0.5 (ie, greater than 
halving of the exposure), indicating a statistically significant interaction between olaparib 
and rifampin.  
As with Study 7, given the lack of any apparent change in elimination t½ of olaparib, the 
changes in olaparib exposure may reflect a change in the extent of drug absorption, in 
this case a decrease in drug absorption possibly transporter protein-mediated (P-
glycoprotein). It is, therefore, recommended that potent CYP3A4 enzyme inducers (eg, 
phenytoin, rifampin, carbamazepine, St John’s Wort) and moderate CYP3A inducers 
(eg, bosentan, efavirenz, etravirine, modafinil, nafcillin) should be avoided during 
olaparib treatment. 
Across both studies, the number and type of AEs reported were in line with what would 
be expected for this patient population and the known safety profile for olaparib.7,22–25 
The majority of AEs reported were of mild or moderate severity. Olaparib showed an 
acceptable tolerability profile, and no new safety findings were observed. Phase III trials 
of olaparib tablet formulation in patients with ovarian, breast, pancreatic, and gastric 
cancers are ongoing.26–32  
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Conclusions 
In these Phase I studies, exposure to olaparib as assessed by AUC and Cmax was 
increased when a single 100 mg dose was given in combination with the CYP3A4 
inhibitor, itraconazole. Conversely, olaparib exposure was decreased when a single  
300 mg dose was given in combination with the CYP3A4 inducer, rifampin. Based on 
these findings, it is recommended that potent and moderate CYP3A4 enzyme inhibitors 
and inducers should be avoided during olaparib treatment. No clinically relevant safety 
signals were observed when a single dose of olaparib was administered in combination 
with itraconazole or rifampin. The safety data for olaparib tablets were consistent with 
the known safety profile of this drug. 
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